FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579605781> ?p ?o ?g. }

• W2579605781 abstract "Abstract Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered to be the most intensive post remission treatment consisting of high-dose chemoradiotherapy and allo-immune mechanisms. However, the powerful anti-leukemic effects of this treatment are counterbalanced by a high incidence of treatment-related mortality (TRM), thus allo- SCT has not always been considered superior to chemotherapy. The aim of this study was to investigate the efficacy of allo-SCT as a postremission treatment in patients with intermediate/poor risk AML in first CR. Previously untreated patients aged 15 – 50 years were eligible. Patients received standard induction therapy consisting of cytarabine (100 mg/ m2 d1–7) and idarubicin (12 mg/m2 d1- 3). If the patients did not achieve remission after the first induction therapy, then the same induction therapy was given again. The patients who achieved CR were randomized into an intensified short-course postremission chemotherapy group (arm A) or conventional JALSG postremission chemotherapy group (arm B). Patients were also categorized into good, intermediate or poor risk groups by risk factors selected from previous JALSG AML trials using univariate and multivariate analyses. Intermediate or poor risk patients with living siblings were tissue typed. If an HLA matched sibling was found it was assumed that the patient would receive allo-SCT during CR1 (donor group). Those without living or HLA matched siblings were assigned to the no-donor group that continued receiving chemotherapy. The disease-free survival (DFS) rates, the relapse incidence rates (RI), TRM and the overall survival (OS) rates of the patients of the donor group were compared with those of the no-donor group on the basis of the intention to treat. Result: Of 503 patients aged 15 – 50 years old registered between December 1997 and July 2001, 397 achieved complete remission (CR). The 5-year OS rate of the CR patients with good, intermediate and poor risk was 68%, 43% and 29%, respectively (p&lt;0.001), showing successful stratification by the JALSG scoring system. Among those who achieved CR with intermediate or poor risk, 75 with and 95 without an HLA matched sibling were assigned to the donor and no-donor groups, respectively. The actual risk of relapse at 8 years was significantly lower in the donor group than in the no-donor group (54% versus 78%, p=0.009). The TRM did not significantly differ between the donor group and the no-donor group (16% versus 17%, p= 0.948). The lower relapse rate in the donor group resulted in a significantly better DFS compared with the no-donor group (38% versus 18%, p=0.017). The significant superiority of DFS in the donor group was translated into a higher OS rate, however, the difference in OS between the two groups did not reach statistical significance (45% versus 28%, p=0.089). The OS of the patients younger than 35 years of age were comparable between the donor group and the no-donor group. However, the OS in the donor group patients older than 36 years old was significantly better than the other (47% versus 23%, p= 0.032). Conclusions: Our study showed that allo-SCT reduced the risk of relapse and contributed to the survival advantage of AML patients aged from 36 to 50 years old with intermediate or poor risk." @default.
• W2579605781 created "2017-01-26" @default.
• W2579605781 creator A5001496361 @default.
• W2579605781 creator A5002669103 @default.
• W2579605781 creator A5013146671 @default.
• W2579605781 creator A5017994748 @default.
• W2579605781 creator A5018101881 @default.
• W2579605781 creator A5030723283 @default.
• W2579605781 creator A5037291528 @default.
• W2579605781 creator A5050827716 @default.
• W2579605781 creator A5056635560 @default.
• W2579605781 creator A5063488239 @default.
• W2579605781 creator A5066881350 @default.
• W2579605781 creator A5070702322 @default.
• W2579605781 creator A5074811645 @default.
• W2579605781 creator A5087299748 @default.
• W2579605781 date "2008-11-16" @default.
• W2579605781 modified "2023-09-27" @default.
• W2579605781 title "Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myelogenous Leukemia (AML). Final Analysis of JALSG AML97 Study" @default.
• W2579605781 doi "https://doi.org/10.1182/blood.v112.11.347.347" @default.
• W2579605781 hasPublicationYear "2008" @default.
• W2579605781 type Work @default.
• W2579605781 sameAs 2579605781 @default.
• W2579605781 citedByCount "1" @default.
• W2579605781 crossrefType "journal-article" @default.
• W2579605781 hasAuthorship W2579605781A5001496361 @default.
• W2579605781 hasAuthorship W2579605781A5002669103 @default.
• W2579605781 hasAuthorship W2579605781A5013146671 @default.
• W2579605781 hasAuthorship W2579605781A5017994748 @default.
• W2579605781 hasAuthorship W2579605781A5018101881 @default.
• W2579605781 hasAuthorship W2579605781A5030723283 @default.
• W2579605781 hasAuthorship W2579605781A5037291528 @default.
• W2579605781 hasAuthorship W2579605781A5050827716 @default.
• W2579605781 hasAuthorship W2579605781A5056635560 @default.
• W2579605781 hasAuthorship W2579605781A5063488239 @default.
• W2579605781 hasAuthorship W2579605781A5066881350 @default.
• W2579605781 hasAuthorship W2579605781A5070702322 @default.
• W2579605781 hasAuthorship W2579605781A5074811645 @default.
• W2579605781 hasAuthorship W2579605781A5087299748 @default.
• W2579605781 hasConcept C120665830 @default.
• W2579605781 hasConcept C121332964 @default.
• W2579605781 hasConcept C126322002 @default.
• W2579605781 hasConcept C141071460 @default.
• W2579605781 hasConcept C143998085 @default.
• W2579605781 hasConcept C144301174 @default.
• W2579605781 hasConcept C2776611710 @default.
• W2579605781 hasConcept C2776694085 @default.
• W2579605781 hasConcept C2777408962 @default.
• W2579605781 hasConcept C2778041864 @default.
• W2579605781 hasConcept C2778461978 @default.
• W2579605781 hasConcept C2779117419 @default.
• W2579605781 hasConcept C2911091166 @default.
• W2579605781 hasConcept C38180746 @default.
• W2579605781 hasConcept C61511704 @default.
• W2579605781 hasConcept C71924100 @default.
• W2579605781 hasConceptScore W2579605781C120665830 @default.
• W2579605781 hasConceptScore W2579605781C121332964 @default.
• W2579605781 hasConceptScore W2579605781C126322002 @default.
• W2579605781 hasConceptScore W2579605781C141071460 @default.
• W2579605781 hasConceptScore W2579605781C143998085 @default.
• W2579605781 hasConceptScore W2579605781C144301174 @default.
• W2579605781 hasConceptScore W2579605781C2776611710 @default.
• W2579605781 hasConceptScore W2579605781C2776694085 @default.
• W2579605781 hasConceptScore W2579605781C2777408962 @default.
• W2579605781 hasConceptScore W2579605781C2778041864 @default.
• W2579605781 hasConceptScore W2579605781C2778461978 @default.
• W2579605781 hasConceptScore W2579605781C2779117419 @default.
• W2579605781 hasConceptScore W2579605781C2911091166 @default.
• W2579605781 hasConceptScore W2579605781C38180746 @default.
• W2579605781 hasConceptScore W2579605781C61511704 @default.
• W2579605781 hasConceptScore W2579605781C71924100 @default.
• W2579605781 hasLocation W25796057811 @default.
• W2579605781 hasOpenAccess W2579605781 @default.
• W2579605781 hasPrimaryLocation W25796057811 @default.
• W2579605781 hasRelatedWork W1968660331 @default.
• W2579605781 hasRelatedWork W1980180443 @default.
• W2579605781 hasRelatedWork W2001421019 @default.
• W2579605781 hasRelatedWork W2337047365 @default.
• W2579605781 hasRelatedWork W2341077074 @default.
• W2579605781 hasRelatedWork W2364957068 @default.
• W2579605781 hasRelatedWork W2368559970 @default.
• W2579605781 hasRelatedWork W2385946468 @default.
• W2579605781 hasRelatedWork W2489968887 @default.
• W2579605781 hasRelatedWork W2498568625 @default.
• W2579605781 hasRelatedWork W2549794571 @default.
• W2579605781 hasRelatedWork W2565598817 @default.
• W2579605781 hasRelatedWork W2571767884 @default.
• W2579605781 hasRelatedWork W2577650897 @default.
• W2579605781 hasRelatedWork W2578657405 @default.
• W2579605781 hasRelatedWork W2588600888 @default.
• W2579605781 hasRelatedWork W2593449435 @default.
• W2579605781 hasRelatedWork W2778733725 @default.
• W2579605781 hasRelatedWork W3001609119 @default.
• W2579605781 hasRelatedWork W3197903518 @default.
• W2579605781 isParatext "false" @default.
• W2579605781 isRetracted "false" @default.
• W2579605781 magId "2579605781" @default.
• W2579605781 workType "article" @default.